Related Experiment Video
Updated: Jan 27, 2026
Murine Corneal Transplantation: A Model to Study the Most Common Form of Solid Organ Transplantation
Published on: November 17, 2014
Management of dyslipidemia in adult solid organ transplant recipients
Bruce A Warden1, P Barton Duell1
1Center for Preventive Cardiology, Knight Cardiovascular Institute, Oregon Health & Science University, Portland, OR, USA.
Insights
Managing dyslipidemia in solid organ transplantation (SOT) is crucial. Immunosuppressants can worsen lipid profiles, necessitating careful management to improve graft survival and reduce cardiovascular risks.
Area of Science:
- Cardiology
- Transplantation Medicine
- Pharmacology
Background:
- Solid organ transplantation (SOT) has improved end-stage disease treatment but revealed significant cardiovascular disease burden.
- Cardiovascular disease is a leading cause of morbidity and mortality post-SOT.
- Dyslipidemia is a frequent, modifiable risk factor for post-transplant cardiovascular disease.
Purpose of the Study:
- To review the impact of immunosuppressive medications on dyslipidemia in SOT recipients.
- To discuss the role of statins and other lipid-lowering therapies in SOT.
- To highlight challenges in managing dyslipidemia, including drug interactions.
Main Methods:
- Literature review of studies on dyslipidemia in SOT.
- Analysis of immunosuppressive drug effects on lipoproteins.
- Examination of lipid-lowering therapy efficacy and safety in SOT.
Main Results:
- Immunosuppressants commonly cause dyslipidemia through off-target metabolic effects.
- Statins improve outcomes in SOT, reducing graft vasculopathy, rejection, and improving survival.
- Limited data exist for non-statin therapies; drug interactions pose significant risks.
Conclusions:
- Effective dyslipidemia management is essential for SOT patient outcomes.
- Statins are foundational for lipid management in SOT.
- Careful consideration of drug interactions is vital for safe and effective lipid-lowering therapy in SOT recipients.
Abstract:
Solid organ transplantation (SOT) has revolutionized treatment of end-stage disease. Improvements in the SOT continuum of care have unmasked a significant burden of cardiovascular disease, manifesting as a leading cause of morbidity and mortality. Although several risk factors for development of post-transplant cardiovascular disease exist, dyslipidemia remains one of the most frequent and modifiable risks. An important contributor to dyslipidemia in SOT recipients is the off-target metabolic effects of immunosuppressive medications, which may alter lipoproteins and their metabolism. Dyslipidemia management is paramount as lipid-lowering therapy with statins has demonstrated reductions in graft vasculopathy, decreased rejection rates, and improved survival. Several nonstatin medication options are available, but data supporting their benefit in the SOT population are minimal, typically extrapolated from studies in the general population. Further compounding dyslipidemia management is the complex interplay of drug interactions between lipid-lowering and immunosuppressant medications, which can result in serious toxicity and/or therapeutic failure.
Related Concept Videos
01:16Kidney Transplant III: Nursing Management
02:37Metallic Solids
All metallic solids exhibit high thermal and electrical conductivity, metallic luster, and malleability....
02:22Structures of Solids
02:18Network Covalent Solids
To break or to melt a covalent network solid, covalent bonds must be broken. Because covalent bonds are relatively strong, covalent network solids are typically...
02:54Molecular and Ionic Solids
Molecular Solids
Molecular crystalline solids, such as ice, sucrose (table sugar), and iodine, are solids that are composed of neutral molecules as their constituent units. These molecules are held together by weak intermolecular forces such as London dispersion forces, dipole-dipole interactions, or hydrogen bonds, which...
02:26Molecular Comparison of Gases, Liquids, and Solids